Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases

References

• HartsellWFYajnikSPalliation of bone metastasesHalperinECPerezCABradyLWPerez and Brady’s Principles and Practice of Radiation Oncology5th edPhiladelphiaLippincott Williams & Wilkins200819861999
   Google Scholar
• SartorOOverview of samarium-153 lexidronam in the treatment of painful metastatic bone diseaseRev Urol20046Suppl 10S3S1216985930
   PubMedGoogle Scholar
• JanjanNLutzSTBedwinekJMTherapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation OncologyJ Palliat Med200912541742619416037
   PubMed Web of Science ®Google Scholar
• LutzSBerkLChangEPalliative radiotherapy for bone metastases: an ASTRO evidence-based guidelineInt J Radiat Oncol Biol Phys201179496597621277118
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN)NCCN Clinical Practice Guidelines in Oncology – prostate cancer. Version 2 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed July 1, 2013
   Google Scholar
• BaumanGCharetteMReidRSathyaJRadiopharmaceuticals for the palliation of painful bone metastasis: a systemic reviewRadiother Oncol200575325827016299924
   PubMed Web of Science ®Google Scholar
• ChiacchioSMazzarriSLorenzoniARadionuclide therapy and integrated protocols for bone metastasesQ J Nucl Med Mol Imaging201155443144721738116
   PubMed Web of Science ®Google Scholar
• FinlayIGMasonMDShelleyMRadioisotopes for the palliation of metastatic bone cancer: a systematic reviewLancet Oncol20056639240015925817
   PubMed Web of Science ®Google Scholar
• SartorOReidRHHoskinPJSamarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancerUrology200463594094515134985
   PubMed Web of Science ®Google Scholar
• McEwanAJUse of radionuclides for the palliation of bone metastasesSemin Radiat Oncol200010210311410727599
   PubMed Web of Science ®Google Scholar
• TianJHZhangJMHouQTMulticentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in ChinaEur J Nucl Med1999261279933654
   PubMedGoogle Scholar
• VengalilSO’SullivanJMParkerCCUse of radionuclides in metastatic prostate cancer: pain relief and beyondCurr Opin Support Palliat Care20126331031522710580
   PubMed Web of Science ®Google Scholar
• ClassRJostMMoseSRadioimmunoglobulins and nonsealed radionuclide therapyHalperinECPerezCABradyLWPerez and Brady’s Principles and Practice of Radiation Oncology5th edPhiladelphiaLippincott Williams & Wilkins2008583598
   Google Scholar
• National Cancer InstituteFDA approval for radium 223 dichloride2013 Available from: http://www.cancer.gov/cancertopics/druginfo/fda-radium-223-dichlorideAccessed June 15, 2013
   Google Scholar
• NilssonSStrangBAksnesAKA randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancerEur J Cancer201248567868622341993
   PubMed Web of Science ®Google Scholar
• NilssonSFranzénLParkerCTwo-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesClin Genitourin Cancer2013111202623021204
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDUpdated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)J Clin Oncol201230SupplLBA4512
   Web of Science ®Google Scholar
• EaryJCollinsCStabinMSamarium-153-EDTMP biodistribution and dosimetry estimationJ Nucl Med1993347103110367686217
   PubMed Web of Science ®Google Scholar
• RescheIChatalJFPeckingAA dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastasesEur J Cancer19973310158315919389919
   PubMed Web of Science ®Google Scholar
• SerafiniANSamarium Sm-153 lexidronam for the palliation of bone pain associated with metastasesCancer200088Suppl 122934293910898337
   PubMedGoogle Scholar
• SerafiniANHoustonSJRescheIPalliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trialJ Clin Oncol1998164157415819552068
   PubMed Web of Science ®Google Scholar
• SartorOReidRHBushnellDLQuickDPEllPJSafety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone painCancer2007109363764317167764
   PubMed Web of Science ®Google Scholar
• FizaziKBenzebocPLumbrosoJPhase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration resistant prostate cancerJ Clin Oncol200927152429243519364971
   PubMed Web of Science ®Google Scholar
• LinJSinibaldiVJCarducciMAPhase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancerUrol Oncol200929667067519962920
   PubMed Web of Science ®Google Scholar
• MorrisMJPandit-TaskarNCarrasquilloJPhase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerJ Clin Oncol200927152436244219364960
   PubMed Web of Science ®Google Scholar
• RoquéIFigulsMMartinez-ZapataMJScott-BrownMAlonso-CoelloPRadioisotopes for metastatic bone painCochrane Database Syst Rev20117CD00334721735393
   PubMed Web of Science ®Google Scholar
• AndersonPMWisemanGADispenzieriAHigh dose samarium-153 ethylene diamine tetramethylene phophonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastasesJ Clin Oncol200220118919611773169
   PubMed Web of Science ®Google Scholar
• BergerMGrignaniGGiostraA153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patientsAnn Oncol20122371899190522104576
   PubMed Web of Science ®Google Scholar
• LattimerJCCorwinLAStapletonJClinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogsJ Nucl Med19903155865932341893
   PubMed Web of Science ®Google Scholar
• LattimerJCCorwinLAStapletonJClinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMPJ Nucl Med1990318131613252384798
   PubMed Web of Science ®Google Scholar
• SinghAHolmesRAFarhangiMHuman pharmacokinetics of samarium-153 EDTMP in metastatic cancerJ Nucl Med19893011181418182478681
   PubMed Web of Science ®Google Scholar
• FarhanghiMHolmesRAVolkertWALoganWSinghAmolakSamarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancerJ Nucl Med1992338145114581378887
   PubMed Web of Science ®Google Scholar
• CollinsCEaryJFDonaldsonGSamarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trialJ Nucl Med19933411183918448229221
   PubMed Web of Science ®Google Scholar